Sei Investments Co. Grows Position in Xeris Biopharma Holdings, Inc. $XERS

Sei Investments Co. grew its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 45.0% in the first quarter, Holdings Channel.com reports. The firm owned 579,210 shares of the company’s stock after buying an additional 179,863 shares during the period. Sei Investments Co.’s holdings in Xeris Biopharma were worth $3,359,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently modified their holdings of the business. UBS Group AG boosted its holdings in Xeris Biopharma by 682.4% in the 3rd quarter. UBS Group AG now owns 1,782,734 shares of the company’s stock worth $14,511,000 after buying an additional 1,554,869 shares during the period. Vanguard Group Inc. lifted its position in shares of Xeris Biopharma by 13.8% during the fourth quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company’s stock worth $87,815,000 after acquiring an additional 1,358,760 shares in the last quarter. Qube Research & Technologies Ltd boosted its holdings in shares of Xeris Biopharma by 67.5% in the second quarter. Qube Research & Technologies Ltd now owns 3,089,771 shares of the company’s stock worth $14,429,000 after acquiring an additional 1,245,188 shares during the period. Goldman Sachs Group Inc. grew its position in shares of Xeris Biopharma by 75.4% in the first quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock valued at $15,317,000 after purchasing an additional 1,199,435 shares in the last quarter. Finally, Granahan Investment Management LLC grew its position in shares of Xeris Biopharma by 249.4% in the fourth quarter. Granahan Investment Management LLC now owns 1,223,404 shares of the company’s stock valued at $9,604,000 after purchasing an additional 873,236 shares in the last quarter. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Stock Performance

NASDAQ XERS opened at $7.93 on Friday. Xeris Biopharma Holdings, Inc. has a 1 year low of $5.25 and a 1 year high of $10.08. The company has a debt-to-equity ratio of 17.00, a current ratio of 2.12 and a quick ratio of 1.50. The stock has a market capitalization of $1.37 billion, a PE ratio of -72.09 and a beta of 0.66. The company’s 50 day simple moving average is $7.68 and its two-hundred day simple moving average is $6.80.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.19). The firm had revenue of $92.10 million for the quarter, compared to analysts’ expectations of $90.12 million. Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 158.10%. Analysts predict that Xeris Biopharma Holdings, Inc. will post 0.12 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on XERS. Wall Street Zen cut Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a report on Saturday. Weiss Ratings raised Xeris Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, July 23rd. Four analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $10.80.

Insider Activity at Xeris Biopharma

In related news, Director John Johnson sold 15,000 shares of the business’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $6.09, for a total transaction of $91,350.00. Following the completion of the transaction, the director directly owned 683,083 shares in the company, valued at $4,159,975.47. The trade was a 2.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Beth Hecht sold 16,666 shares of the business’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $8.01, for a total value of $133,494.66. Following the transaction, the insider owned 1,144,462 shares of the company’s stock, valued at approximately $9,167,140.62. The trade was a 1.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 266,499 shares of company stock valued at $1,996,417 in the last ninety days. 4.35% of the stock is currently owned by corporate insiders.

Xeris Biopharma Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.